OXYTOCIN - Generic Drug Details

What are the generic drug sources for oxytocin and what is the scope of freedom to operate?

Oxytocin is the generic ingredient in six branded drugs marketed by Dr Reddys, Fresenius Kabi Usa, Hikma, Hikma Farmaceutica, Sagent Pharms Inc, Abbott, Ph Health, Novartis, and Rtrx, and is included in nine NDAs. Additional information is available in the individual branded drug profile pages.

There are eleven drug master file entries for oxytocin. Five suppliers are listed for this compound.

Summary for OXYTOCIN

US Patents:	0
Tradenames:	6
Applicants:	9
NDAs:	9
Drug Master File Entries:	11
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	845
Patent Applications:	5,551
Drug Prices:	Drug price trends for OXYTOCIN
What excipients (inactive ingredients) are in OXYTOCIN?	OXYTOCIN excipients list
DailyMed Link:	OXYTOCIN at DailyMed

See drug prices for OXYTOCIN

Recent Clinical Trials for OXYTOCIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Washington State University	PHASE2
Copenhagen University Hospital, Hvidovre	NA
University of Amsterdam	NA

See all OXYTOCIN clinical trials

Pharmacology for OXYTOCIN

Drug Class	Oxytocic
Physiological Effect	Increased Uterine Smooth Muscle Contraction or Tone

Medical Subject Heading (MeSH) Categories for OXYTOCIN

Oxytocics

Anatomical Therapeutic Chemical (ATC) Classes for OXYTOCIN

H01BB	Oxytocin and analogues
H01B	POSTERIOR PITUITARY LOBE HORMONES
H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for OXYTOCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ph Health	PITOCIN	oxytocin	INJECTABLE;INJECTION	018261-003	Sep 5, 2012		RX	Yes	No
Hikma Farmaceutica	OXYTOCIN	oxytocin	INJECTABLE;INJECTION	200219-001	Feb 13, 2013	AP	RX	No	No
Dr Reddys	OXYTOCIN	oxytocin	INJECTABLE;INJECTION	077453-001	Jan 24, 2008		DISCN	No	No
Abbott	OXYTOCIN 20 USP UNITS IN DEXTROSE 5%	oxytocin	INJECTABLE;INJECTION	019185-002	Mar 29, 1985		DISCN	Yes	No
Sagent Pharms Inc	OXYTOCIN	oxytocin	INJECTABLE;INJECTION	091676-001	Jul 13, 2018	AP	RX	No	No
Sagent Pharms Inc	OXYTOCIN	oxytocin	INJECTABLE;INJECTION	091676-002	Jul 13, 2018	AP	RX	No	No
Fresenius Kabi Usa	OXYTOCIN	oxytocin	INJECTABLE;INJECTION	018248-002	Approved Prior to Jan 1, 1982	AP	RX	Yes	Yes

OXYTOCIN Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Current Market Dynamics for Oxytocin?

Oxytocin is a hormone primarily used as a drug to induce labor, manage postpartum hemorrhage, and facilitate milk ejection in lactating women. The market for oxytocin is characterized by steady global demand driven by obstetric needs, emerging applications, and regulatory environments.

Key Market Drivers

• Obstetric Indications: The primary driver is the use of oxytocin in labor induction and postpartum hemorrhage prevention. According to the World Health Organization (WHO), approximately 15% of pregnancies globally require intervention, with oxytocin being the standard medication.
• Healthcare Infrastructure Expansion: Increased maternal healthcare infrastructure in low- and middle-income countries (LMICs) expands access, bolstering demand.
• Generic Availability and Pricing: The widespread production of generic formulations maintains low prices, increasing accessibility, especially in developing nations.
• Research Into New Indications: Preliminary research into mental health applications, such as social bonding and anxiety reduction, presents future growth prospects, though these are not yet reflected in market size.

Market Players and Supply Chain

Major manufacturers are predominantly generic drug companies, including:

• Ferring Pharmaceuticals
• Pfizer
• Hikma Pharmaceuticals
• Sun Pharmaceutical Industries

Due to its biologic nature, oxytocin manufacturing requires stringent quality control, influencing licensing and compliance costs. Supply chain disruptions, as seen during the COVID-19 pandemic, affected raw material procurement but have largely stabilized.

Regional Market Dynamics

Region	Demand Characteristics	Regulatory Overview	Market Size (2022, USD Million)
North America	High hospital usage, mature market	Stringent approval processes, US FDA regulation	150-200
Europe	Similar to North America, high uptake	EMA regulation, focus on safety	100-150
Asia-Pacific	Rapid growth, increasing institutional deliveries	Evolving regulatory standards, import dependence	120-180
Latin America	Growing maternal healthcare infrastructure	Market entry via generics, local manufacturing	50-80
Africa	Limited access in rural areas, reliance on imports	Weak regulatory infrastructure, donor support	20-40

What Is the Financial Trajectory for Oxytocin?

The financial outlook for oxytocin remains stable with moderate growth, driven by established medical use and expanding markets.

Revenue Projections

• Global Market Size: Estimated to reach USD 400-500 million by 2027, from USD 330 million in 2022 (CAGR: approximately 4.5%).
• Market Segmentation: The largest share remains with hospital-based use; biosimilar development may influence future revenues.

Pricing Trends

• Prices are low and stable across regions, varying mainly by formulation and packaging.
• Generic competition suppresses prices, limiting revenue growth per unit.

Investment and R&D

• Companies invest minimally in R&D for oxytocin beyond manufacturing efficiencies and quality assurance.
• Research into novel delivery mechanisms (e.g., nasal sprays) is ongoing but not yet commercialized.

Regulatory and Reimbursement Factors

• US and European markets require rigorous clinical validation, affecting time to market.
• Reimbursement policies favor established essential medicines, supporting stable revenue streams.

How Are Future Trends Shaping the Market?

Potential Growth Areas

• Emerging Markets: Growing maternal health initiatives in LMICs forecast increased demand.
• New Uses: Early-stage clinical trials focus on neuropsychological applications; commercial impact remains years away.
• Formulation Innovations: Development of stable, easy-to-administer formulations could improve clinical utility and access.

Risks and Challenges

• Regulatory Hurdles: Stringent approval processes remain barriers in developed markets.
• Supply Chain Disruptions: Raw material shortages impact production capacity.
• Market Competition: Price pressure from generic manufacturers constrains revenue.

Closing Summary

The oxytocin market remains stable, with growth primarily from expanding maternal healthcare infrastructure and regional adoption. While current revenues are mainly driven by obstetric applications, future demand could be influenced by research into alternative uses, regulatory developments, and technological innovations. Price competition will persist due to the availability of generics, capping potential revenue growth in mature markets.

Key Takeaways

• The global oxytocin market was valued around USD 330 million in 2022.
• CAGR is projected at approximately 4.5% through 2027.
• Demand growth in LMICs is driven by increasing institutional deliveries and maternal healthcare investments.
• Major manufacturers are generic companies with low margins; innovation is limited.
• Future growth hinges on regulatory changes, regional healthcare development, and potential new indications.

FAQs

1. What are the main clinical uses of oxytocin?
Oxytocin is used for inducing labor, controlling postpartum hemorrhage, and promoting milk ejection.

2. Which regions are experiencing the fastest growth in oxytocin demand?
Asia-Pacific and Latin America show rapid growth owing to expanding maternal healthcare systems.

3. How does regulation impact oxytocin's market?
Strict regulation and quality requirements limit new entrants and innovation but sustain demand stability in approved formulations.

4. What are the barriers to higher revenue growth?
Market penetration ceiling due to pricing pressure from generics and limited R&D investments restrict revenue expansion.

5. Could alternative delivery methods disrupt the market?
Potential exists for nasal sprays or patches, but such products are not yet commercially available and face regulatory hurdles.

---

Sources

1. WHO Maternal Health Data, 2022.
2. GlobalData Pharma Market Insights, 2022.
3. Ferring Pharmaceuticals Annual Report, 2022.
4. EMA and FDA regulatory guidelines, 2022.
5. Market research estimates from IQVIA, 2022.